Insight Molecular Diagnostics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $113.2M
- Price
- $3.46
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.37%
- Volume
- 153.9K
About
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Quick stats
Shares outstanding32.7M
Computed float25.5M
Float / shares77.9%
Cash runway (months)3.9
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001642380
Websitehttps://imdxinc.com
AI Summary
AI-generated1/16
minorneutralother
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
Insight Molecular Diagnostics (Nasdaq: IMDX) announced it will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth "BIG10" Conference on Thursday, September 10, 2026, at the Metropolitan Club in New York City.
CEO Josh Riggs and CFO Andrea James will represent the company in one-on-one meetings; investors can schedule time through their Lake Street sales representative.
The release is a routine investor-relations scheduling notice with no new financial, clinical, or operational disclosure about the diagnostics company or its GraftAssure transplant-testing platform.